Patents by Inventor Robert A. Huertas
Robert A. Huertas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092788Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: September 6, 2023Publication date: March 21, 2024Applicant: Omeros CorporationInventors: Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung, Sudheer Babu Vaddela
-
Patent number: 11807641Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: GrantFiled: December 4, 2020Date of Patent: November 7, 2023Assignee: Omeros CorporationInventors: Michael Cicirelli, Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Loren Michael Price, Jennifer Tsoung, Sudheer Babu Vaddela
-
Patent number: 11661418Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: GrantFiled: December 4, 2020Date of Patent: May 30, 2023Assignee: OMEROS CORPORATIONInventors: Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung
-
Publication number: 20230145071Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.Type: ApplicationFiled: November 30, 2022Publication date: May 11, 2023Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
-
Patent number: 11584714Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.Type: GrantFiled: May 29, 2019Date of Patent: February 21, 2023Assignee: OMEROS CORPORATIONInventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
-
Patent number: 11352321Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: GrantFiled: February 28, 2019Date of Patent: June 7, 2022Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
-
Publication number: 20210179612Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: December 4, 2020Publication date: June 17, 2021Inventors: Neil S. CUTSHALL, Jennifer Lynn GAGE, Do Yeon KWON, Thomas L. LITTLE, Markus METZ, Peter Kurt NOLLERT VON SPECHT, Jennifer TSOUNG, Jeremiah H. NGUYEN, Melinda DAVIS, Robert Huerta LEMUS, Santosh Kumar KESHIPEDDY, Sara Rebecca GOLDSTEIN
-
Publication number: 20210171512Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: December 4, 2020Publication date: June 10, 2021Inventors: Neil S. CUTSHALL, Jennifer Lynn GAGE, Sara Rebecca GOLDSTEIN, Santosh Kumar KESHIPEDDY, Do Yeon KWON, Robert Huerta LEMUS, Thomas L. LITTLE, Markus METZ, Peter Kurt NOLLERT VON SPECHT, Loren Michael PRICE, Jennifer TSOUNG
-
Publication number: 20210171531Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: December 4, 2020Publication date: June 10, 2021Inventors: Michael CICIRELLI, Neil S. CUTSHALL, Jennifer Lynn GAGE, Sara Rebecca GOLDSTEIN, Santosh Kumar KESHIPEDDY, Do Yeon KWON, Robert Huerta LEMUS, Thomas L. LITTLE, Markus METZ, Jeremiah H. NGUYEN, Peter Kurt NOLLERT VON SPECHT, Loren Michael PRICE, Jennifer TSOUNG, Sudheer Babu VADDELA
-
Patent number: 10807946Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.Type: GrantFiled: March 25, 2019Date of Patent: October 20, 2020Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, Raja K. Reddy, Paul D. Van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Publication number: 20190367452Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.Type: ApplicationFiled: May 29, 2019Publication date: December 5, 2019Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
-
Publication number: 20190330144Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: ApplicationFiled: February 28, 2019Publication date: October 31, 2019Inventors: Jorge E GOMEZ-GALENO, Scott J. HECKER, Qun DANG, Mali Venkat REDDY, Zhili SUN, Matthew P. GROTE, Thanh Huu NGUYEN, Robert Huerta LEMUS, Haiqing LI
-
Publication number: 20190218176Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.Type: ApplicationFiled: March 25, 2019Publication date: July 18, 2019Inventors: Jorge E. GOMEZ-GALENO, Raja K. Reddy, Paul D. Van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Patent number: 10239829Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: GrantFiled: June 5, 2017Date of Patent: March 26, 2019Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, Raja K. Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Patent number: 10221130Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: GrantFiled: September 29, 2017Date of Patent: March 5, 2019Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
-
Publication number: 20180022695Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: ApplicationFiled: September 29, 2017Publication date: January 25, 2018Inventors: Jorge E. Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
-
Patent number: 9783494Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: GrantFiled: November 26, 2014Date of Patent: October 10, 2017Assignee: METABASIS THERAPEUTICS, INC.Inventors: Jorge E. Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
-
Publication number: 20170275246Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: June 5, 2017Publication date: September 28, 2017Inventors: Jorge E. Gomez-Galeno, Raja K. Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Patent number: 9701626Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: GrantFiled: September 21, 2015Date of Patent: July 11, 2017Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, Raja K. Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Publication number: 20160009639Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: September 21, 2015Publication date: January 14, 2016Inventors: Jorge E. Gomez-Galeno, Raja K. Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo